RetaCalc
Protocol library
SingleInvestigationalPhase 2Moderate confidenceSourced

MK-677 / Ibutamoren

An oral, non-peptide ghrelin receptor agonist studied in several controlled trials. It is investigational and has no injectable formulation.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Human Study
Healthy adults aged 60 to 81 years

25 mg orally once daily in a two-year randomized study

The trial measured growth hormone, IGF-1 and body composition; it did not authorise anti-ageing use.

View source
Human Study
Adults with mild-to-moderate Alzheimer disease

25 mg orally once daily for 12 months

The large randomized trial did not slow clinical progression.

View source

Evidence summary

An oral, non-peptide ghrelin receptor agonist studied in several controlled trials. It is investigational and has no injectable formulation.

Protocol basis

The protocol summary uses oral human trials and makes clear that trial quantities and surrogate hormone changes do not create an injectable or wellness protocol.

What remains uncertain

An approved indication, durable clinical benefit and a favourable long-term benefit-risk balance remain unestablished.

Warnings and contraindications

MK-677 is an oral small molecule, not an injectable peptide.
Growth hormone and IGF-1 increases are surrogate effects rather than proof of broad clinical benefit.
Long studies reported metabolic and fluid-related adverse effects that require clinical interpretation.